DDInter170 DDInter1376
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28,
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Bedaquiline {u} (Compound) resembles {v} (Compound) Bromodiphenhydramine
Bedaquiline {u} (Compound) resembles {v} (Compound) Orphenadrine
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
Bedaquiline {u} (Compound) is included by {v} (Pharmacologic Class) Diarylquinolines
Bedaquiline {u} (Compound) causes {v} (Side Effect) Arrhythmia
Bedaquiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Bedaquiline (Compound) resembles Bromodiphenhydramine (Compound)
Bedaquiline (Compound) resembles Orphenadrine (Compound)
Bedaquiline (Compound) binds CYP3A4 (Gene)
Bedaquiline (Compound) is included by Diarylquinolines (Pharmacologic Class)
Bedaquiline (Compound) causes Arrhythmia (Side Effect)
Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Bedaquiline may lead to a major life threatening interaction when taken with Clarithromycin
Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib